
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VXB-241
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : TCGX
Deal Size : $100.0 million
Deal Type : Series B Financing
Vicebio Secures $100M For RSV/hMPV Vaccine Phase 1 Clinical Study
Details : The financing aims to support the clinical development of VXB-241, which is being evaluated in the early-stage clinical studies for the targeting both RSV and hMPV viruses.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 23, 2024
Lead Product(s) : VXB-241
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : TCGX
Deal Size : $100.0 million
Deal Type : Series B Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VXB-241
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
Details : VXB-241 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 15, 2024
Lead Product(s) : VXB-241
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VXB-211
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Medicxi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RSV vaccine candidate (VXB-211), best-in-class efficacy as a ready-to-use fully liquid formulation,for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : VXB-211
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Medicxi
Deal Size : Inapplicable
Deal Type : Inapplicable
